4//SEC Filing
Zago Wagner M. 4
Accession 0001140361-23-028870
CIK 0001559053other
Filed
Jun 6, 8:00 PM ET
Accepted
Jun 7, 9:49 PM ET
Size
17.4 KB
Accession
0001140361-23-028870
Insider Transaction Report
Form 4
Zago Wagner M.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-06-07−15,000→ 0 totalExercise: $29.81Exp: 2024-02-04→ Ordinary Shares (15,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2023-06-07−4,000→ 66,000 totalExercise: $12.15Exp: 2030-02-25→ Ordinary Shares (4,000 underlying) - Exercise/Conversion
Ordinary Shares, par value $0.01 per share
2023-06-07$12.15/sh+4,000$48,600→ 19,000 total - Sale
Ordinary Shares, par value $0.01 per share
2023-06-07$71.96/sh−3,759$270,479→ 294 total - Sale
Ordinary Shares, par value $0.01 per share
2023-06-07$73.14/sh−294$21,503→ 0 total - Exercise/Conversion
Ordinary Shares, par value $0.01 per share
2023-06-07$29.81/sh+15,000$447,150→ 15,000 total - Sale
Ordinary Shares, par value $0.01 per share
2023-06-07$70.02/sh−2,943$206,061→ 16,057 total - Sale
Ordinary Shares, par value $0.01 per share
2023-06-07$70.99/sh−12,004$852,181→ 4,053 total
Footnotes (6)
- [F1]The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023.
- [F2]The transaction was executed in multiple trades in prices ranging from $69.54 to $70.53, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4.
- [F3]The transaction was executed in multiple trades in prices ranging from $70.545 to $71.4925, inclusive.
- [F4]The transaction was executed in multiple trades in prices ranging from $71.57 to $72.41, inclusive.
- [F5]All shares subject to the option have fully vested.
- [F6]The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 25, 2021, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Documents
Issuer
PROTHENA CORP PUBLIC LTD CO
CIK 0001559053
Entity typeother
Related Parties
1- filerCIK 0001708681
Filing Metadata
- Form type
- 4
- Filed
- Jun 6, 8:00 PM ET
- Accepted
- Jun 7, 9:49 PM ET
- Size
- 17.4 KB